WO2005050225A3 - Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84) - Google Patents

Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84) Download PDF

Info

Publication number
WO2005050225A3
WO2005050225A3 PCT/EP2004/011805 EP2004011805W WO2005050225A3 WO 2005050225 A3 WO2005050225 A3 WO 2005050225A3 EP 2004011805 W EP2004011805 W EP 2004011805W WO 2005050225 A3 WO2005050225 A3 WO 2005050225A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
diseases
gpr84
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2004/011805
Other languages
French (fr)
Other versions
WO2005050225A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts, Holger Summer filed Critical Bayer Healthcare Ag
Publication of WO2005050225A2 publication Critical patent/WO2005050225A2/en
Publication of WO2005050225A3 publication Critical patent/WO2005050225A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides a human GPR84 which is associated with the cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, metabolic diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, cancer disorders and reproduction disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, metabolic diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, cancer disorders and reproduction disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of GPR84 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2004/011805 2003-10-31 2004-10-19 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84) WO2005050225A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03025068 2003-10-31
EP03025068.2 2003-10-31

Publications (2)

Publication Number Publication Date
WO2005050225A2 WO2005050225A2 (en) 2005-06-02
WO2005050225A3 true WO2005050225A3 (en) 2005-07-07

Family

ID=34610038

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/011805 WO2005050225A2 (en) 2003-10-31 2004-10-19 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)

Country Status (1)

Country Link
WO (1) WO2005050225A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1929310A2 (en) * 2005-09-02 2008-06-11 Arena Pharmaceuticals, Inc. Human g protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to mcp-1 expression
GB201122146D0 (en) 2011-12-22 2012-02-01 Galapagos Nv Screening methods to identify compounds useful in the prevention and/or treatment of inflammatory conditions
AR089284A1 (en) 2011-12-22 2014-08-13 Galapagos Nv DIHYDROPIRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS OF THE SAME FOR THE TREATMENT OF INFLAMMATORY DISORDERS
GB201506894D0 (en) * 2015-04-23 2015-06-10 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
CA3014774A1 (en) * 2016-02-17 2017-08-24 Children's Medical Center Corporation Ffa1 (gpr40) as a therapeutic target for neural angiogenesis diseases or disorders
WO2023076668A1 (en) * 2021-10-29 2023-05-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for treatment of cancer
WO2024083705A1 (en) * 2022-10-18 2024-04-25 Bayer Aktiengesellschaft Furoindazole derivatives for the treatment of pain

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0853125A2 (en) * 1997-01-09 1998-07-15 Smithkline Beecham Corporation cDNA clone HNFJD15 that encodes a human 7-transmembrane receptor
WO2001066597A2 (en) * 2000-03-06 2001-09-13 Novartis Ag Inflammation-related gene
DE10021474A1 (en) * 2000-05-03 2001-11-08 Michael Brues New monoamine receptor-1 gene, MAR1, useful for diagnosis and treatment of MAR1-related diseases
WO2002077001A2 (en) * 2001-03-09 2002-10-03 Tularik Inc. Novel receptors
WO2003006990A1 (en) * 2001-07-12 2003-01-23 Exelixis, Inc. Modifiers of the p21 pathway and methods of use
US20030054444A1 (en) * 2000-11-14 2003-03-20 Peter Battaglino Novel human G-protein coupled receptor, HGPRBMY8, expressed highly in brain
WO2003054540A1 (en) * 2001-12-19 2003-07-03 Synaptic Pharmaceutical Corporation Dna encoding a human receptor (hp15a) and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0853125A2 (en) * 1997-01-09 1998-07-15 Smithkline Beecham Corporation cDNA clone HNFJD15 that encodes a human 7-transmembrane receptor
WO2001066597A2 (en) * 2000-03-06 2001-09-13 Novartis Ag Inflammation-related gene
DE10021474A1 (en) * 2000-05-03 2001-11-08 Michael Brues New monoamine receptor-1 gene, MAR1, useful for diagnosis and treatment of MAR1-related diseases
US20030054444A1 (en) * 2000-11-14 2003-03-20 Peter Battaglino Novel human G-protein coupled receptor, HGPRBMY8, expressed highly in brain
WO2002077001A2 (en) * 2001-03-09 2002-10-03 Tularik Inc. Novel receptors
WO2003006990A1 (en) * 2001-07-12 2003-01-23 Exelixis, Inc. Modifiers of the p21 pathway and methods of use
WO2003054540A1 (en) * 2001-12-19 2003-07-03 Synaptic Pharmaceutical Corporation Dna encoding a human receptor (hp15a) and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WITTENBERGER T ET AL: "An expressed sequence tag (EST) data mining strategy succeeding in the discovery of new G-protein coupled receptors", JOURNAL OF MOLECULAR BIOLOGY, vol. 307, 30 March 2001 (2001-03-30), pages 799 - 813, XP002191897, ISSN: 0022-2836 *

Also Published As

Publication number Publication date
WO2005050225A2 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
WO2005106492A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 3 (ccr3)
WO2005095973A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54)
WO2005103702A3 (en) Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 2 (cxcr2)
WO2005106471A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4)
WO2005050225A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
WO2005040828A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
WO2005059546A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35)
WO2004082568A3 (en) Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)
WO2005040211A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1)
WO2005040825A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2004104574A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
WO2005108998A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor beta-3 adreno (adrb3)
WO2005103711A3 (en) Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 1 (cxcr1)
WO2004082571A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 86 (gpr86)
WO2005040824A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 24 (gpr24)
WO2005040829A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 17 (gpr17)
WO2004104577A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
WO2005040822A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 25 (gpr25)
WO2004099248A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2)
WO2004106934A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 7 (5-ht7)
WO2004082572A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 87 (gpr87)
WO2005103690A3 (en) Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2)
WO2005040790A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 75 (gpr75)
WO2004106935A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 103 (gpr103)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase